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Key points: 
1. There is no high quality comparative effectiveness research for surgery versus 
pharmacological management or for different surgical techniques.  
2. High quality evidence (randomised controlled trials) is required to inform routine 
decision making for patients with TN and their consultants. 
3. The design and conduct of surgery trials using the standard design has numerous 
challenges (patient preferences, clinician preferences, clinically meaningful outcome 
measures, learning curves for surgical techniques, irreversibility of results)  
4. The ‘cohort multiple RCT’ design is an innovative alternative design that provides 
both long term observational data and a facility for quick and efficient conduct of 
multiple trials. Unlike standard trials, patient information and consent replicate that 
found in routine healthcare wherever possible. 
5. Embedding multiple trials within a cohort of patients with a diagnosis of TN would 
enable the quick and efficient identification and recruitment of patients to trials of a 
variety of interventions, and help provide the information that patients and clinicians 
require. 
 
Synopsis 
Should patients undergo a surgical intervention as soon as they receive a diagnosis of  
trigeminal neuralgia  (TN), or should they wait until pharmacological treatment fails?  
Knowing the answer to this question would help inform patient and clinician decision making. 
To answer this question, randomised controlled trials (RCTs) comparing standard medical 
pharmacological interventions with surgical treatments are needed. This article describes 
some of the challenges that have been encountered in surgical trials for TN, and provides 
some guidance for future trials in this area. One future direction for TN research is to utilise 
the innovative ‘cohort multiple RCT design’. This approach enables multiple trials to be 
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embedded within a single cohort of patients a diagnosis of TN, providing an efficient and 
effective approach to the testing of multiple interventions for TN with each other and with 
usual care. 
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Introduction – which trials are needed? 
Unusually trigeminal neuralgia (TN), a rare disease, can be managed both medically 
(pharmacologically) and surgically, and there is some evidence of the importance of 
psychological therapies. So what trials are needed?  
1. Comparison of medical vs surgical treatments 
Surgical management can yield 100% pain relief for 70% of patients for 10 years 1 2. 
Medical management provides 50% pain relief but becomes less effective over time and 
as the doses is raised result in poorer tolerability 3 . Many of these patients eventually opt 
for surgery but best timing of this is still unknown. 4 Although the majority of patients 
remain on medical management until it fails 5  6, there is evidence that patients prefer 
surgical management . 7 Zakrzewska et al 8 reviewing 220 patients who had posterior 
fossa found 73% said they would have preferred earlier surgery.  
There is also evidence that clinicians/ surgeons support early surgery for 
classical cases of TN and those with positive imaging 9. Others suggest that surgical 
treatments should only be offered after patients become refractory to medical 
management which is defined by Obermann as failure of two drugs 10. Di Stefano et al  6 
in their cohort of 200 patients on medical management suggest that medications remain 
highly effective and only 7% in their cohort needed surgery. 
However, there is no rigorous (i.e. randomised controlled trial RCT) evidence to 
support either an early or delayed surgical management compared to 
pharmacological management of TN.  The recent Cochrane systematic review on 
neurosurgical interventions in TN identified just 11 RCTs involving 496 patients, 11 
however the majority of these trials were biased.  None of the high quality trials 
compared different surgical techniques with each other or compared surgery with 
pharmacological management. The three high quality RCTs compared different surgical 
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techniques with potentially more refined versions of the same technique 11. There were 
no RCTs of microvascular decompression MVD, (the most invasive procedure and only 
non-destructive procedure) but observational data which suggests that it may have the 
best long term outcomes for pain relief. 12 
Given patient and clinician preferences and the lack of evidence to support surgery 
or pharmacological management, the most important research question for the TN 
profession is should patients undergo a surgical intervention as soon as the diagnosis 
has been made (i.e. very early in the course of the condition), or should  they wait until 
the conservative (pharmacological) treatment has failed? In other words, should they 
receive surgical treatment that provides something very close to a cure (albeit not 
necessarily permanent) cure or remain on medication? If early surgery was comparable 
to (or better than medical management) this information would impact on how patients 
viewed their options at the time of diagnosis, and provide more flexibility in the decision 
making process in the early stages. 
 
2. Comparison of the different surgical techniques  
There are an emerging number of studies comparing different techniques, however 
the interpretation of the results of these studies is hampered by differences in the 
outcomes used and the short duration of outcomes. 13 Future trials should use the same 
outcomes and also follow up patients for minimum of 5 years. 1  
 
3. New and comparative drug trials  
Drug trials in TN are few and far between and most drugs used to date have been 
established anti-epileptics. However there is now a potential for a new drug with good 
efficacy and better tolerability to be evaluated. Phase 2 studies have been completed 
using a novel design of enriched enrolment randomized withdrawal (EERW) design in 
which patients are initially screened, and then all are put on the active drug for a set 
period 14.  After this period only those considered to have been responders are allocated 
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to the randomised   part of the trial where the active drug is compared to a placebo. In 
this design there is a set time for the trial but non responders are encouraged to drop 
out.  
Moore et al  15 have done a systematic review of all the pain trials using the EERW 
trial design and suggest that these can play an important role if correctly designed but 
may be difficult to compare outcomes with classical trials. Comparisons of different drugs 
are also required and whether single or multiple drugs should be used 12 . 
 
4. Addition of psychological therapies .  
TN has considerable impact on quality of life and patients live in fear of a recurrence 
of their pain. 16  One small study (n= 15) has shown that spontaneous pain as opposed to 
pain evoked by a trigger could be driven by emotional factors. 17 There is anecdotal 
evidence from surgeons and patients that patients are reluctant to touch their faces after 
surgical treatments in case they trigger an attack, this behaviour is also seen in 
continuation of medications post-surgery especially after stereotactic radiosurgery 
surgery (SRS).   
In summary there are a number of research questions in the field of TN that require 
evidence from well design RCTs. This article describes a number of challenges in the design 
and conduct of trials with a particular emphasis on surgical trials for TN. It will provide some 
pointers for future trials.   
Problems with randomised controlled trials  
This section describes the problems with the design, implementation and interpretation of 
RCTs  of interventions to help patients with their health.  
1. Recruitment  
RCTs often have difficulty recruiting sufficient numbers of patients.  Macdonald et al 18, 
found that less than a third of 114 multicentre, publicly funded UK RCTs recruited their 
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original target number of patients within the time originally specified. Failure to recruit to 
target may have implications for the power and generalisability of trial results. The sample 
populations often do not contain ethnic minorities or other hard to reach groups e.g. elderly 
so making it difficult to apply to general practise. Trials of medical management in TN are all 
very small. 19  
Ethical issues 
In a systematic review of the literature on barriers to participation in RCTs, Ross 20 et 
al found that concerns with information and consent were some of the major reasons why 
both patients and clinicians were unwilling to participate in trials. In routine real world health 
care, patients are rarely told of treatments that their clinicians cannot with certainty provide  
nor are patients told their treatment will be decided by chance 21 . On the other hand, in 
clinical trials providing this type of "full" information before randomisation is regarded as an 
ethical requirement. The consequence of this “full” information is that patients worry about 
the uncertainty of treatment outcome especially if there is the possibility that they may be 
allocated to placebo. It is acknowledged that for clinicians there is a potential conflict of 
interest between what is good for the current patient and what is good for future patients 22. 
These issues are nicely demonstrated in the anecdote in box 1. 
Box 1 here  
In a recent phase II  trial patients were reluctant to be recruited as they had got 
reasonable control and tolerability on their current drugs and were concerned that the new 
drug for TN would upset this balance (currently unpublished). Moreover, in general practice 
patients are often given less information about their treatments than that currently required 
by some ethics committees who are asked to review intervention trials. 
2. Patient preferences 
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Standard "open" (unblinded) pragmatic trials often compare an intervention with 
treatment as usual. Where the "standard care" on offer is available outside the trial, 
however, the only incentive for the patient to participate (apart from altruism) is to receive the 
new intervention. If a patient is allocated to treatment as usual, he or she may withdraw from 
the trial (attrition bias) or exhibit disappointment bias when reporting outcomes. 23   Patients 
with rare diseases are more reluctant to take part in trials for this reason. 24 There may 
therefore be a treatment effect, which results from patient preferences and not from 
therapeutic efficacy 25. This is a major problem in TN were destructive treatments give very 
different results from non destructive methods or if compared to medical therapies. As 
surgery is irreversible patients may prefer to delay this yet when asked specifically about 
timing of MVD the majority in retrospect said they would have wanted surgery earlier.  8  
3. Treatment comparisons 
For conditions with many potential treatment options, there are often multiple trials 
conducted, with each potential treatment being trialled, one at a time, in different populations 
by different research teams, often with heterogeneous outcomes and heterogeneous trial 
populations. Thus when treatments need to be compared, they can only be done by indirect 
methods. The effectiveness of treatments A versus C can be difficult to evaluate if the only 
trials of treatments are A versus B and B versus C exist. Indirect comparisons—where two 
interventions are compared through their relative effect versus a common comparator—can 
succeed, but sometimes result in significant discrepancies compared with the results of head 
to head randomised trials. 26. Many competing interventions have thus not been compared or 
have been compared inaccurately which is a waste of valuable information and money. This 
is a major problem in TN where there are no RCTs of MVD and the RCTs that have been 
done compare surgical techniques and use varying outcome measures at varying time 
points. It has therefore been very difficult to compare not just surgical trials but medical ones 
for the same condition. 
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4. Diagnosis  
An essential of all trials is an accurate description of the participants using evidence 
based diagnostic criteria as this will enable clinicians to determine if the patients in the trial 
are representative of their patients.  TN was  considered to have very clear diagnostic 
criteria but it is now emerging that there are several variants and the nomenclature has 
become confusing with terms such as type 1 and 2  TN or TN with concomitant pain. 27  , 28  
There has also been a group of conditions known as the trigeminal autonomic cephalalgias 
which include four different conditions. Two of them short unilateral neuralgiform headache 
with conjunctival redness tearing (SUNCT)  and short unilateral neuralgiform headache  with 
any autonomic symptom (SUNA) may in fact be yet other variants of TN 29 .   
TN and its variants are unusual in that the pain is episodic and there are unpredictable 
remissions and relapses which makes it even harder to be sure that the end result is due to 
the intervention rather than the natural history of the disorder.    
5. Timing  
New medications undergo a specific standardised pathway in order to become 
registered, but this is not the case for surgical interventions.  A surgical intervention passes 
through many phases of innovation and refining and has a tipping point at which the 
intervention is no longer an innovation but a routine procedure. The tipping point (when 
equipoise is lost) is extremely variable and cannot be predicted thus making the accurate 
timing of RCTs difficult .  30 This has generated what has become known as Buxton's law: 'It 
is always too early [for rigorous evaluation] until suddenly it's too late'. 21   
Thus the newest intervention for TN, SRS was first assessed in an exploratory trial to 
determine its efficacy and this was done in those patients who would benefit most and by 
surgeons who had the freedom to develop and refine the intervention. In 2001 a RCT by 
Flickinger et al  31 of this procedure in a multicenter trial showed that one rather than two 
isocentre were sufficient to provide pain relief without sensory loss, one of the first refining 
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studies. This could have been followed by a pragmatic trial which included a very broad 
population and surgeons with a range of expertise so it represented most closely what 
occurs in general practice. This approach would have provided information on both the short 
and long term outcomes of SRS and could have addressed cost effectiveness and quality of 
life questions if outcomes had been assessed independently. 23 This would have then 
enabled a standard to be set against which audits could be carried out.   Schnurman and 
Kondziolka 32,33 have suggested an alternative approach to this problem  see Box 2  
 
 Box 2 here  
Schnurman  and Kondziolka 33 then applied this to a series of surgical procedures 
including SRS  for TN. They found  for this procedure an equal number of initial studies,16 
with 1250 patients and 16 cohort studies and therefore estimated that the year to PAS was 
10 years , occurring in 2002-3 and years to objective efficacy i.e when accepted by the 
surgical community was 10-11 years. In comparison endovascular coiling of aneurysms took 
only 5 years to objective efficacy. These results are also influenced by accessibility and 
approval of the equipment, the rarity of the disease and the ease with which an RCT can be 
done. The authors conclude that SRS for TN could be evaluated through an RCT.   
 
6. Funding  
Funding is often lacking and estimates of costs of the studies can be difficult to predict 
due to the multiplicity of factors involved, estimates becomes more complicated if the trials 
are multicentred .34 Commercial influences often also come into play and may affect 
surgeons’ involvement. The equipment for SRS is very expensive and in cost evaluations, 
which also take into account quality –adjusted life years, SRS is the most expensive 
procedure of all surgical approaches.35  
 
7. Choice of comparators  
 
12 
 
There are many types of comparator available, but not all comparators are suitable for all 
types of surgery.  Many trials compare surgical intervention to watchful waiting or medical 
treatment and this can be a satisfactory method for chronic conditions. When comparing 
surgical procedures complications may be very different for the two interventions and this 
can affect both patient preference and blinding of outcomes e.g. ablative procedures are 
likely to result in sensory loss whereas decompression of the trigeminal nerve is highly 
unlikely to lead to sensory loss but can result in hearing loss. When the comparator is a 
different surgical technique then the same surgeon may be performing both interventions. 
He/she may be skilled in both but it is equally likely that there is a differential expertise 
between procedures. This then calls for a different approach that takes into account surgical 
expertise. 36  However, using expert surgeons may then result in an inability to generalise to 
all neurosurgeons.  
 
8. Surgeons' equipoise 
Equipoise means that there is uncertainty regarding whether the trial treatment will be 
more beneficial to people than the comparator. Individual surgeons often have preferences 
for one intervention over another and thus may not be willing to take part in a clinical trial. 
Career surgeons are selected for traits that include comfort with making important clinical 
decisions quickly with incomplete information. This quality, required for decisive action 
during operations, may make it difficult for them to be consciously uncertain which of two 
treatments is better. Equipoise as to whether a treatment is effective or not is required in the 
scientific medical community but is not required from individual surgeons unless they have to 
perform two different types of surgical intervention in the trial. This can be a problem in 
neurosurgical interventions in TN as some procedures are destructive whereas others aim to 
preserve sensory function and so neurosurgeons may be reluctant to randomise patients to 
ablative procedures which they may consider using only in those patients who are not 
medically fit for major surgery.  
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9. Interventions 
In pharmacological trials the main intervention in most cases is the drug alone, however, 
surgical interventions are highly complex and include the procedure itself, the surgeon, the 
surgical team and pre and post operative care . 9, 15, 23, 37 
All surgical interventions have two learning curves, both of which are variable. The first is 
perfecting the surgical techniques and the second is the personal learning curve of the 
surgeon. This has been well illustrated when looking at the drop in mortality and 
complication rates of MVD  for TN over the years, mortality was over 1% and now is around 
0.2-0.4%. 38 
10. Blinding  
Although it is considered important that both patients and health care professionals  are 
blinded to ensure that exaggerated estimates of treatment are not reported.it can lead to 
patients  being unsure of what is the  required outcome and opting for an intermediate 
outcome. 39  However this is much more difficult to do in non pharmacological trials then 
pharmacological trials. 40 In a review of 110 RCTs evaluating treatment of pharmacological 
and non-pharmacological interventions in patients with hip or knee osteoarthritis it was 
showed that blinding was more difficult to achieve and unblinding occurred more frequently 
in non-pharmacological intervention studies. Blinding of surgical procedures of patients/care 
providers is possible if the methods to blind are common. These include   treatments that 
have the same physical characteristics and the same route of administration, surgical 
interventions that leave similar scars and post-operative care e.g number of isocentres for 
delivery of radiation to the trigeminal nerve but difficult to do when a using a frame or not for 
neuronavigation for delivery of radiofrequency thermocoagulation. 41   Blinding is improved if 
surgeons who performed the operation have no further contact with the patients. In studies 
where treatments are radically different e.g surgical versus drug therapy or where control 
treatments are usual care or waiting list, then blinding of one group becomes impossible. In 
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some trials it may be easy to blind the patient to the procedure but the subsequent clinical 
outcomes could result in unblinding e.g different doses of radiation will lead to different 
complications. There is considerable evidence to show that unblinded outcomes assessment 
is associated with significantly larger treatment effects than blinded outcomes assessment. 
42  When it is suspected that blinding may be problematical it is useful to perform an 
assessment e.g ask the patients which treatment they think they were given, as to whether 
the blinding was successful but current methods to do this assessment  are far from 
standardised. 40 
 
11. Randomisation  
 The strength of the RCT is that by randomisation, assuming adequate concealment of 
group allocation, the distribution of any known or unknown prognostic factors at baseline 
arises purely by chance, thus randomisation is the main method that ensures that allocation 
bias is eliminated at baseline. 30  It is often possible to randomise in the operating theatre as 
shown in Erdine et al’s trial of pulsed and continuous radiofrequency thermocoagulation for 
patients with TN. 43  It is essential when analysing the studies to ensure that the patients 
remain in the groups that they were randomised to at the beginning of the study, i.e use an 
intention to treat analysis.  
12. Outcome measures  
Outcomes need to be varied and include clinical, patient reported and economic both in 
the short and long term. Developing valid reproducible generalisable outcome measures that 
are then suitable for meta-analysis is complex and requires considerable consensus.  
Boutron et al    44 have suggested a range of different types of outcome measures which are 
listed in Box 3 .  
BOX 3 here  
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Different specialties have tried to develop some core outcome measures that will 
then lend themselves to meta-analysis and in determining the sample size of a study.  e.g 
pain 45, orthopaedics 46. Often some generic questionnaires are needed in order to compare 
to other data and the International Association for the Study of Pain ( IASP ) have suggested 
a range of measures that should be used  in clinical trials of pain patients IMMPACT  45.  
Measures using questionnaires need to undergo testing which include  its test-retest 
reliability (reproducibility), responsiveness (ability to detect clinically important change), and 
validity 47.  The major outcome measure of surgical treatments for TN has been pain relief 
and there are very few reports of quality of life or other patient important outcomes. 48  The 
Barrow Neurological Institute (BNI) scoring system 49 (which evaluates pain intensity and 
numbness) was first used in SRS and has  been adopted by several centres. However, this 
has not undergone psychometric testing and it is not clear how it is administered e.g from 
the medical notes or with the patient 50 .   Reddy et al 51,52   have reported on the use of the 
BNI and a Visual Analog  Scale (VAS)  to determine the minimum clinically important 
difference in pain improvement after an MVD 51  , SRS  52 but the sample sizes were small.  
To overcome these shortcomings Lee et al   53 developed the Brief Pain Inventory Facial for 
which they have also estimated the minimum clinically important differences  50 and have 
applied it pre and post surgery to a group of patients undergoing SRS 54and MVD. 55 
Poolman et al   46 have highlighted other difficulties in using outcome instruments, 
these include cultural and linguistic considerations, physical and mental capacity of patients 
and the statistical methods used to evaluate them.   Many outcome measures are in the form 
of questionnaires which then need to be administered in an independent way to prevent the 
assessor being blinded by the researcher e.g. patient completing questionnaire in the 
presence of or help of the researchers.  
  As.  Zarins 47  point out that in many trials the outcome measures are then applied in 
a modified form which if they have not been tested invalidates them . Poolman et al  46 
showed in their review of outcome measures used in orthopaedic RCTs that ten trials (37%) 
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used modified outcome measures and nine did not describe how the modified instrument 
was validated and retested.  Some questionnaires are generic and can be applied to a wide 
variety of conditions e.g SF36 but can have little meaning for a specific entity. Thus, a 
questionnaire that has been validated for one clinical condition is not always valid when 
applied to a different clinical entity. Pan et al 56 used the SF36 in his cohort of patients but 
then did not find any other published study that used this tool and so went on to convert his 
data to the BNI as they could then compare their data. The only validated questionnaires 
used in TN have been the verbal rating scale of pain, Hospital Anxiety and Depression Scale 
to measure mood and the Brief Pain Inventory Facial for quality of life.   
One of the major difficulties when comparing medical against surgical trials in TN is 
that for the latter 100% pain relief is expected whereas for dug management it is set at 50% 
in line with all other pain conditions. Patients’ expectations of other outcomes may be 
different from medical versus surgical treatments.    
Future approaches 
Some important requirements of future trials are listed in box 4 
Box 4 here  
There have been various attempts to address the difficulties in designing surgical 
trials e.g. the formation of the Balliol Colloquium which reports its findings in a series of 
publications in the Lancet .  30, 37  , 57 have put forward their IDEAL model of the stages in 
surgical practise as shown in Box 5.  
 
Box 5 here  
At all stages of the development of surgical practise it is possible to use RCT 
designs. Although newer trial designs have been created to address  some of the above 
problems none of these designs either increase the number of patients randomised and/or 
address the cost/ funding problem with standard trials.  More recently, a number of studies 
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are embedding trials within cohorts as a way of overcoming these problems. These are 
described below. 
 
Trials within Cohorts 
 
Cohort multiple RCT design: In 2010, Relton et al 58published their theoretical 
article describing the ‘cohort multiple randomised controlled trial’ design. This is an 
innovative approach to the design and conduct of pragmatic or comparative effectiveness 
trials – trials which aim to inform routine healthcare decision making 58.  The design aims to 
address many of the problems associated with standard RCT design which may reduce the 
generalizability of results, potentially introduce post randomisation selection bias and create 
a sub-optimal system for producing the information required for healthcare decision making.  
Since the publication of the theoretical article a number of triallists have started using the 
design in the UK, Canada, and Netherlands, including both trials with usual care as 
comparator e.g. trials within the PICNIC cohort study of patients with rectal cancer 
(conference presentations).  Figure 1 and box 6 illustrate how this may be used for TN. 
 
Insert figure 1 here  
Insert box 6 here  
Figure 1 A ‘cohort multiple RCT’ approach to TN  
The rationale for this approach to informed consent is twofold. Firstly, as the primary 
motive for patients to enter clinical trials is not altruism, but their own direct benefit as 
patients. Clinical trial informed consent procedures should, therefore, put the needs of the 
patient at the centre; that is, patients should not be told about treatments that they might not 
then receive, nor should they be told that their treatment will be allocated by chance. 
Secondly, the greater the similarity between patients’ experiences in trials and their 
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experiences in routine care, then the greater the generalisability of the trial results to patients 
in routine care.  
The ‘cohort multiple RCT’ design will not only yield much needed data on long term 
prognosis of this condition but will allow both surgical and drug treatments and even 
adjunctive psychological treatments to all be evaluated alongside each other. It will also take 
into account patients and surgeons preferences, as it will be possible to evaluate the 
acceptability of different procedures by following up those patients who refuse the offered 
RCT.  
Research using standard RCT designs often struggles to recruit and consequently 
has to randomly allocate all patients to either group in equal proportions to maximise 
statistical power within their total sample. The large numbers of patients recruited to the 
cohort in the cmRCT approach increases the statistical power of any RCTs and enables 
unequal randomisation. For example, a small number of patients could be randomly selected 
to be offered an expensive treatment and compared with a larger number of unselected 
patients. Unequal randomisation thus improves the efficiency of trials of high cost 
interventions e.g. SRS, compared with equal allocation. These factors strengthen the 
inferences in the trial, lower treatment costs compared with standard designs (that is, once 
the cohort is established, it potentially allows for rapid and cheap recruitment of patients for 
any RCT), and allows significant cost savings for trials of expensive treatments. 
Furthermore, data on treatment refusers provides information on the acceptability of the 
treatment and thus the generalisability of the trial results.  
RCT within a cohort design: More recently, the cmRCT design has been adapted 
by the Finnish Degenerative Meniscal Lesion Study (FIDELITY) 59 to be able to incorporate 
one or more placebo trials of surgery within their cohort of patients with knee pain with 
meniscus injury. All patients recruited are informed that they may be offered a placebo 
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intervention at some point. Sihvonen 59 et al describe this as an ‘RCT within-a-cohort’ 
design.  
 
Conclusion 
This article has described some of the challenges encountered in trials and 
particularly surgical trials for TN, and provides some guidance for future trials. One future 
direction for TN research is to use designs which embed trials with cohorts such as the 
innovative ‘cohort multiple RCT design’. This approach enables multiple trials to be 
embedded within a single cohort of patients with  TN, providing an efficient and effective 
approach to the testing of multiple interventions for TN with each other and with usual care. 
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Box 1 Problems of informed consent  “a Canadian surgeon participating in a workshop 
on designing clinical trials. The Canadian surgeon reported explaining a trial to a potential 
participant and the fact that there was uncertainty about the best treatment. At the end of 
the discussion the surgeon asked the patient if he had any questions. “Yes” said the patient, 
“Can you refer me to a surgeon who does know what is the best treatment for me?”  
(Relton, Clare (2009) A new design for pragmatic randomised controlled trials: a 'Patient Cohort' RCT of 
treatment by a homeopath for menopausal hot flushes. PhD thesis, University of Sheffield. 
http://etheses.whiterose.ac.uk/6644/ ) 
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Box 2 : The progressive scholarly acceptance (PSA ) method  
 
Aim : use publications to  chart progress from innovation to general acceptance  
Method : 
 Assumes that once there is broad acceptance that an innovation is effective the 
next series of papers focus on refining the technique. 
 The point at which there are more papers on refinement than efficacy or 
effectiveness becomes the PSA point  
 Assess authoring group to see if the procedure was being disseminated and the 
quality of the publications 
 Results :  
 Refining studies increase efficiency, decrease costs and may have a moderate 
effect on outcomes 
 Initial efficacy studies have a higher impact on patient care.  
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Box 3 Types of outcome measures  
1. “Patient-reported outcomes” (e.g., pain and disabilities), when the patient 
is the outcome assessor. 
2. “Outcomes that do not suppose a contact between patients and outcome 
assessors” (e.g MRI ) 
3. “Outcomes that suppose a contact between patients and outcome 
assessors” (e.g.,  sensory testing ). 
4. “Clinical events and therapeutic outcomes that will be determined by the 
interaction between patients and care providers” (e.g. length of hospitalization, 
treatment failure, and repeat surgery), in which the care provider is the outcome 
assessor.  
5. “Clinical events and therapeutic outcomes that will be assessed from data 
on the       medical form” (e.g., death, significant complication, short term, long 
terms). 
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Box 5  Stages in IDEAL : Innovation, Development, Exploration, Assessment, and 
Long-term study   
• Stages 0 - the initial pre-human work and development 
• Stage 1 idea - first time it is used in human beings.   
• Stage 2a development - few patients recruited, few surgeons for the intervention 
• Stage 2b exploration - early exploratory phase, reports appearing  
• Stage 3 assessment -  procedure is part of many surgeons’ practices 
• Stage 4 long term study surveillance – databases set up, long term outcomes, 
quality assurance  
.  
 
 
 
 
Box 4 Requirements of future trials  
 Use of multi-disciplinary team and a range of different skills e.g  methodologists, 
statisticians,  database designers, patients 
 Completion of a systematic review not only of clinical material but animal studies  
 Clinical trials protocol published before the trial start so they can be modified if 
necessary  
 All trials registered on trial sites such as clinicaltrials.gov prior to their completion 
so it is transparent that the protocol outcomes are used.  
 The results published regardless of whether they are positive or negative. All 
RCTs should be reporting using the CONSORT  
31 
 
 
 
 
Box 6 The key features of the ‘cohort multiple RCT’ design  
I. All patients with a diagnosis of TN are recruited into a large observational cohort 
study, all receive treatment as usual (which may include medical or surgical 
options) 
II. Appropriate easily collected outcome measures are chosen and measured at 
regular intervals for the whole cohort – including description of treatment as usual. 
 
For each randomised control trial in the field of TN e.g. MVD  or a new drug 
III. All patients who are eligible for the trial are identified from the cohort “NA”. 
IV. Using randomisation a selection of patients” nA "are identified and then offered 
trial intervention  “nA” 
V. The outcomes of those randomly selected ”nA” are then compared with the 
outcomes of those eligible patients not selected (but who were eligible to be 
selected) “NA- nA” 
VI. The information given to patients and the consents sought from patients are as 
similar as possible to those found in routine care. All cohort patients consent to 
provide observational data at the outset; however, consent to "try" a particular 
intervention is sought only from those offered that intervention, thus replicating the 
patient centred information and consent procedures that exist in routine health 
care, where clinicians provide patients with the information they need, at the time 
they need it.  
32 
 
 
 
